Mast cell survival and mediator secretion in response to hypoxia

PLoS ONE

Volumn 5, Issue 8, 2010, Pages

  Gulliksson, Magdalena ^a   Carvalho, Ricardo F S ^a   Ullerås, Erik ^b   Nilsson, Gunnar ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIMYCIN; CD30 ANTIGEN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; OXYGEN; AUTACOID; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA;

ARTICLE; AUTOCRINE EFFECT; CELL CULTURE; CELL FUNCTION; CELL HYPOXIA; CELL STIMULATION; CELL SURVIVAL; CHRONIC INFLAMMATION; CONTROLLED STUDY; CYTOKINE RELEASE; HOST RESISTANCE; HUMAN; HUMAN CELL; MAST CELL; MAST CELL DEGRANULATION; MEDIATOR RELEASE; UMBILICAL CORD BLOOD; CELL LINE; CYTOLOGY; DEGRANULATION; DRUG EFFECT; METABOLISM; SECRETION;

ANTIGENS, CD30; CALCIMYCIN; CELL DEGRANULATION; CELL HYPOXIA; CELL LINE; CELL SURVIVAL; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INFLAMMATION MEDIATORS; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MAST CELLS;

EID: 77957872226     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012360     Document Type: Article

References (33)

1. Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM, Williams CM, et al. (2005) Mast cells as ''tunable'' effector and immunoregulatory cells: Recent advances. Annu Rev Immunol 23: 749-786.
2. Ribatti D, Crivellato E, Roccaro AM, Ria R, Vacca A (2004) Mast cell contribution to angiogenesis related to tumour progression. Clin Exp Allergy 34: 1660-1664.
3. Metz M, Maurer M (2007) Mast cells-key effector cells in immune responses. Trends Immunol 28: 234-241.
4. Lee K, Roth RA, LaPres JJ (2007) Hypoxia, drug therapy and toxicity. Pharmacol Ther 113: 229-246.
5. Norrby K (2002) Mast cells and angiogenesis. APMIS 110: 355-371.
6. Nilsson G, Costa JJ, Metcalfe DD (1999) Mast cells and basophils. In: JI Gallin, RSnyderman, eds. Inflammation: Basic Principles and Clinical Correlates. Philadelphia, PA: Lippincott-Raven publications. pp 97-117.
7. Murdoch C, Muthana M, Lewis CE (2005) Hypoxia regulates macrophage functions in inflammation. J Immunol 175: 6257-6263.
8. Fischer M, Harvima IT, Carvalho RFS, Möller C, Naukkarinen A, et al. (2006) Mast cell CD30 ligand is up-regulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion. J Clin Invest 116: 2748-2756.
9. Oskeritzian CA, Zhao W, Pozez AL, Cohen NM, Grimes M, et al. (2004) Neutralizing endogenous IL-6 renders mast cells of the MCT type from lung, but not the MCTC type from skin and lung, susceptible to human recombinant IL-4-induced apoptosis. J Immunol 172: 593-600.
10. Yanagida M, Fukamachi H, Ohgami K, Kuwaki T, Ishii H, et al. (1995) Effects of T-helper 2-type cytokines, interleukin-3 (IL-3), IL-4, IL-5, and IL-6 on the survival of cultured human mast cells. Blood 86: 3705-3714.
11. Cruse G, Cockerill S, Bradding P (2008) IgE alone promotes human lung mast cell survival through the autocrine production of IL-6. BMC Immunol 9: 1-9.
12. Bradding P, Walls AF, Holgate ST (2006) The role of the mast cell in the pathophysiology of asthma. J Allergy Clin Immunol 117: 1277-1284.
13. Wasserman SI (1987) The mast cell and synovial inflammation. or, what's a nice cell like you doing in a joint like this. Arthritis Rheum 27: 841-844.
14. Theoharides TC, Conti P (2004) Mast cells: the JEKYLL and HYDE of tumor growth. Trends Immunol 25: 235-241.
15. Steiner DR, Gonzalez NC, Wood JG (2003) Mast cells mediate the microvascular inflammatory response to systemic hypoxia. J Appl Physiol 94: 325-334.
16. Jeong HJ, Chung HS, Lee BR, Kim SJ, Yoo SJ, et al. (2003) Expression of proinflammatory cytokines via HIF-1alpha and NF-kappaB activation on desferrioxamine-stimulated HMC-1 cells. Biochem Biophys Res Commun 306: 805-811.
17. Zhang Q, Oh CK, Messadi DV, Duong HS, Kelly AP, et al. (2006) Hypoxiainduced HIF-1 alpha accumulation is augmented in a co-culture of keloid fibroblasts and human mast cells: involvement of ERK1/2 and PI-3K/Akt. Exp Cell Res 312: 145-155.
18. Soule BP, Brown JM, Kushnir-Sukhov NM, Simone NL, Mitchell JB, et al. (2007) Effects of gamma radiation on FcepsilonRI and TLR-mediated mast cell activation. J Immunol 179: 3276-3286.
19. Endoh I, Di Girolamo N, Hampartzoumian T, Cameron B, Geczy CL, et al. (2007) Ultraviolet B irradiation selectively increases the production of interleukin-8 in human cord blood-derived mast cells. Clin Exp Immunol 148: 161-167.
20. Fei P, Wang W, Kim SH, Wang S, Burns TF, et al. (2004) Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth. Cancer Cell 6: 597-609.
21. Stenmark KR, Fagan KA, Frid MG (2006) Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res 99: 675-691.
22. Demasi M, Cleland LG, Cook-Johnson RJ, Caughey GE, James MJ (2003) Effects of hypoxia on monocyte inflammatory mediator production: Dissociation between changes in cyclooxygenase-2 expression and eicosanoid synthesis. J Biol Chem 278: 38607-38616.
23. Saito H, Ebisawa M, Tachimoto H, Shichijo M, Fukagawa K, et al. (1996) Selective growth of human mast cells induced by steel factor, IL-6, and prostaglandin E2 from cord blood mononuclear cells. J Immunol 157: 343-350.
24. Walczak-Drzewiecka A, Ratajewski M, Wagner W, Dastych J (2008) HIF- 1alpha is up-regulated in activated mast cells by a process that involves calcineurin and NFAT. J Immunol 181: 1665-1672.
25. Matsui H, Ihara Y, Fujio Y, Kunisada K, Akira S, et al. (1999) Induction of interleukin (IL)-6 by hypoxia is mediated by nuclear factor (NF)-kappa B and NF-IL6 in cardiac myocytes. Cardiovasc Res 42: 104-112.
26. Suzuki-Nishimura T, Swartz HM (1998) Characterization of redox activity in resting and activated mast cells by reduction and reoxidation of lipophilic nitroxides. Gen Pharmacol 31: 617-623.
27. Marshall JS (2004) Mast-cell responses to pathogens. Nat Rev Immunol 4: 787-799.
28. Singh M, Saini HK (2003) Resident cardiac mast cells and ischemia-reperfusion injury. J Cardiovasc Pharmacol Ther 8: 135-148.
29. Chan RK, Ibrahim SI, Verna N, Carroll M, Moore FD, et al. (2003) Ischaemiareperfusion is an event triggered by immune complexes and complement. Br J Surg 90: 1470-1478.
30. Gulliksson M, Palmberg L, Nilsson G, Ahlstedt S, Kumlin M (2006) Release of prostaglandin D2 and leukotriene C4 in response to hyperosmolar stimulation of mast cells. Allergy 61: 1473-1479.
31. Molin D, Fischer M, Xiang Z, Larsson U, Harvima I, et al. (2001) Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease. Br J Hematol 114: 616-623.
32. Gulliksson M, Brunnstrom A, Johannesson M, Backman L, Nilsson G, et al. (2007) Expression of 15-lipoxygenase type-1 in human mast cells. Biochim Biophys Acta 1771: 1156-1165.
33. Sundstrom M, Vliagoftis H, Karlberg P, Butterfield JH, Nilsson K, et al. (2003) Functional and phenotypic studies of two variants of a human mast cell line with a distinct set of mutations in the c-kit proto-oncogene. Immunology 108: 89-97.